newsfilter
← Latest News
Business Wire·

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or